MCH ADVISORY RESEARCHMain site ↗
Health Care

Health Care Services

9 companies under coverage.

Coverage

Health Care Services


Equity Research

DaVita HealthCare Partners Inc (DVA)

BUY. 12-month probability-weighted target $215 (+19% vs spot). Gross Margin explains 65% of Monte Carlo outcome variance.

DVAEquity ResearchMonte Carlo
9 September 2026Rating: BUY · +14.4%
Equity Research

Cigna Corp (CI)

HOLD. 12-month probability-weighted target $273 (-1% vs spot). Gross Margin explains 68% of Monte Carlo outcome variance.

CIEquity ResearchMonte Carlo
9 September 2026Rating: HOLD · -3.6%
Equity Research

Chemed Corp (CHE)

HOLD. 12-month probability-weighted target $516 (-1% vs spot). Gross Margin explains 49% of Monte Carlo outcome variance.

CHEEquity ResearchMonte Carlo
9 September 2026Rating: HOLD · -10.8%
Equity Research

CVS Health Corp (CVS)

HOLD. 12-month probability-weighted target $103 (+7% vs spot). Gross Margin explains 68% of Monte Carlo outcome variance.

CVSEquity ResearchMonte Carlo
9 September 2026Rating: HOLD · -16.3%
Equity Research

Sotera Health Co (SHC)

HOLD. 12-month probability-weighted target $17 (-6% vs spot). P/E Multiple explains 73% of Monte Carlo outcome variance.

SHCEquity ResearchMonte Carlo
9 September 2026Rating: HOLD · -29.9%
Equity Research

Laboratory Corporation of America Holdings (LH)

SELL. 12-month probability-weighted target $281 (-14% vs spot). Gross Margin explains 58% of Monte Carlo outcome variance.

LHEquity ResearchMonte Carlo
9 September 2026Rating: SELL · -31.7%
Equity Research

Quest Diagnostics Incorporated (DGX)

SELL. 12-month probability-weighted target $204 (-14% vs spot). Gross Margin explains 57% of Monte Carlo outcome variance.

DGXEquity ResearchMonte Carlo
9 September 2026Rating: SELL · -33.5%
Equity Research

BrightSpring Health Services, Inc. Common Stock (BTSG)

SELL. 12-month probability-weighted target $40 (-36% vs spot). Gross Margin explains 66% of Monte Carlo outcome variance.

BTSGEquity ResearchMonte Carlo
9 September 2026Rating: SELL · -50.6%
Equity Research

Hims Hers Health Inc (HIMS)

SELL. 12-month probability-weighted target $12 (-56% vs spot). Gross Margin explains 67% of Monte Carlo outcome variance.

HIMSEquity ResearchMonte Carlo
9 September 2026Rating: SELL · -67.3%
MCH ADVISORY SERVICES · All research · Research, not personalised investment advicemchadvisoryservices.com ↗ · Research Standard v4 (decision-level) · Research OS ros-1.20.0 · US-listed